fehb glp 1 MCT2D Audit Finds Anti-Obesity Drugs a
Description
Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

Prescription drugs continue to be a primary driver of employer-sponsored health care costs

If youre looking into GLP-1 medications for weight loss, youve probably come across two big names: semaglutide and tirzepatide. So whats the difference
Please remember this product may take up to 3 months for you to see craving and gut health improvement

Here's what you need to know:
